Literature DB >> 15569630

Setting the stage for transformation: HTLV-1 Tax inhibition of p53 function.

Cynthia A Pise-Masison1, John N Brady.   

Abstract

Human T-lymphotropic virus type 1 (HTLV-1) is the causative agent of adult T-cell leukemia and tropical spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM). Although the precise mechanism of HTLV-1 oncogenesis remains unclear, the pathogenesis has been linked to the pleiotropic activity of the viral transcriptional activator protein Tax. Tax has been shown to regulate viral and cellular gene expression and to functionally interfere with proteins involved in cell-cycle progression and DNA repair. This review will concentrate on the ability of Tax to promote cellular proliferation through activation of the NF-kappaB pathway while inhibiting the cell-cycle checkpoint and apoptotic function of the tumor suppressor gene p53.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15569630     DOI: 10.2741/1586

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  12 in total

Review 1.  NF-κB as a target for oncogenic viruses.

Authors:  Shao-Cong Sun; Ethel Cesarman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

2.  HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition.

Authors:  Ling Gao; Hongju Deng; Haibo Zhao; Angela Hirbe; John Harding; Lee Ratner; Katherine Weilbaecher
Journal:  Blood       Date:  2005-08-23       Impact factor: 22.113

3.  Multiple Pathways Control the Reactivation of Telomerase in HTLV-I-Associated Leukemia.

Authors:  Marcia Bellon; Christophe Nicot
Journal:  Int J Cancer Oncol       Date:  2015-06-02

4.  Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors.

Authors:  Katerina V Gurova; Jason E Hill; Canhui Guo; Anatoly Prokvolit; Lyudmila G Burdelya; Eugenia Samoylova; Anna V Khodyakova; Ram Ganapathi; Mahrukh Ganapathi; Natalia D Tararova; Dmitry Bosykh; Dmitriy Lvovskiy; Thomas R Webb; George R Stark; Andrei V Gudkov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-15       Impact factor: 11.205

Review 5.  HTLV-1 and apoptosis: role in cellular transformation and recent advances in therapeutic approaches.

Authors:  John M Taylor; Christophe Nicot
Journal:  Apoptosis       Date:  2008-06       Impact factor: 4.677

6.  Small-molecule inhibitor which reactivates p53 in human T-cell leukemia virus type 1-transformed cells.

Authors:  Kyung-Jin Jung; Arindam Dasgupta; Keven Huang; Soo-Jin Jeong; Cynthia Pise-Masison; Katerina V Gurova; John N Brady
Journal:  J Virol       Date:  2008-06-11       Impact factor: 5.103

7.  HTLV-1 Tax: centrosome amplification and cancer.

Authors:  Anne Pumfery; Cynthia de la Fuente; Fatah Kashanchi
Journal:  Retrovirology       Date:  2006-08-09       Impact factor: 4.602

8.  Tax impairs DNA replication forks and increases DNA breaks in specific oncogenic genome regions.

Authors:  Hassiba Chaib-Mezrag; Delphine Lemaçon; Hélène Fontaine; Marcia Bellon; Xue Tao Bai; Marjorie Drac; Arnaud Coquelle; Christophe Nicot
Journal:  Mol Cancer       Date:  2014-09-04       Impact factor: 27.401

9.  Epstein - Barr virus transforming protein LMP-1 alters B cells gene expression by promoting accumulation of the oncoprotein ΔNp73α.

Authors:  Rosita Accardi; Ikbal Fathallah; Henri Gruffat; Giuseppe Mariggiò; Florence Le Calvez-Kelm; Catherine Voegele; Birke Bartosch; Hector Hernandez-Vargas; James McKay; Bakary S Sylla; Evelyne Manet; Massimo Tommasino
Journal:  PLoS Pathog       Date:  2013-03-14       Impact factor: 6.823

10.  p53 Activation following Rift Valley fever virus infection contributes to cell death and viral production.

Authors:  Dana Austin; Alan Baer; Lindsay Lundberg; Nazly Shafagati; Annalise Schoonmaker; Aarthi Narayanan; Taissia Popova; Jean Jacques Panthier; Fatah Kashanchi; Charles Bailey; Kylene Kehn-Hall
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.